Asia Pacific Home Infusion Therapy Market

The Asia Pacific home infusion therapy market is expected to grow from US$ 3,340.35 million in 2022 to US$ 5,725.65 million by 2028. It is estimated to grow at a CAGR of 9.4% from 2022 to 2028.

Increasing Healthcare Potential of Developing Economies and Rising Prevalence of Healthcare-Associated

Infections is Driving Asia Pacific Home Infusion Therapy Market

Developing countries report a high prevalence of chronic diseases due to significant shifts in people’s lifestyles. Leading pharmaceutical companies have been focusing on increasing their reach across emerging markets by expanding their distribution networks and augmented manufacturing capabilities. 

In developing countries, the number of patients receiving home infusion therapy has been limited in the past. Even though hospitals have rapidly adopted smart infusion pumps integrated with features such as electronic health records (EHR) integration and medication safety software, the majority of home infusion service providers continue to use traditional pumps. However, developing countries are focused on improving their healthcare infrastructure and services, which is encouraging the healthcare sector to upgrade these products and services. Moreover, significant investments in research and development play a key role in the technological upgrade of products and services in emerging countries. With the increasing availability of such upgraded medical offerings, their use is likely to rise in these countries in the future.

Due to the COVID-19 pandemic, hospitals were under huge pressure to cater to a vast number of patients, which resulted in overpopulated emergency rooms (ERs), and overwhelmed doctors and medical staff; therefore, the healthcare sectors in developing countries witnessed a crucial shift to homecare settings. Additionally, many patients withdrew from treatments within hospital settings due to the fear of contracting COVID-19, making home care a good option. In addition, patients were prone to hospital-acquired infections or healthcare-associated infections (HAIs) while receiving services in hospitals or other healthcare facilities. With high morbidity and mortality rates, HAIs cost healthcare systems billions of dollars annually. With growing infection rates, there is an increased focus on reducing the incidence of HAIs, owing to the huge costs associated with treating these infections that exert additional economic burdens on the healthcare system. Thus, due to COVID-19 pandemic, home infusion is perceived as an effective treatment option to reduce the risk of getting the HAIs, which serves as a significant opportunity for the home infusion therapy market.

Asia Pacific Home Infusion Therapy Market Overview

The Asia Pacific home infusion therapy market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China held the largest market share in 2021, and India is expected to register a significant CAGR in the market. The market growth in these countries is attributed to the increasing prevalence of chronic diseases, the rising geriatric population, the growing presence of home infusion therapy providers, and the rising number of government initiatives. The Chinese government has adopted Healthy China 2030 to facilitate healthcare services within the nation while delivering great benefits worldwide. The population in the country is more prone to infectious, chronic, and acute diseases. China faces a high burden of lung cancer, colorectal cancer, esophageal cancer, heart disease, and diabetes. Further, the growing presence of local key players is boosting the growth of the home infusion therapy market in China. Manufacturers are focusing on expanding their strategic global presence and specialized expertise with exclusive technological capabilities, leading to the expansion of the home infusion therapy market in China. Hence, the rise in the prevalence of diabetes and chronic diseases, the increase in the geriatric population, and the surge in the number of regional players are expected to propel the growth of the home infusion therapy market in China during the forecast period.  

Asia Pacific Home Infusion Therapy Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Home Infusion Therapy Market Segmentation

The Asia Pacific home infusion therapy market is segmented into product, application, route of administration and country.

Based on product, the home infusion therapy market is segmented into infusion pumps, intravenous sets, IV cannulas, and needleless connectors. The home infusion therapy market segment is sub segmented into insulin pumps, elastomeric pumps, syringe pumps, and others. The infusion pumps segment held the largest market share in 2022.  

Based on application, the home infusion therapy market is segmented into enteral nutrition, anti-infective, endocrinology, hydration therapy, chemotherapy, specialty pharmaceuticals, and others. The anti-infective segment held the largest share of the market in 2022.

Based on route of administration, the home infusion therapy market is segmented into intramuscular, subcutaneously, and epidural. The intramuscular segment held the largest share of the market in 2022. 

Based on country, the Asia Pacific home infusion therapy market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China dominated the market in 2022.  

B. Braun Melsungen AG; Baxter International Inc; Nipro Corp; Becton Dickinson and Co; Fresenius Kabi AG; ICU Medical Inc; JMS Co Ltd; Terumo Corp are the leading companies operating in the Asia Pacific home infusion therapy market.

Asia Pacific Home Infusion Therapy Market Strategic Insights

Asia Pacific Home Infusion Therapy Market Segmentation Analysis

Asia Pacific Home Infusion Therapy Market Report Highlights

Asia Pacific Home Infusion Therapy Report Scope

Asia Pacific Home Infusion Therapy Market Country and Regional Insights